Novara Mark David 4

4 · TANDEM DIABETES CARE INC · Filed May 19, 2026

AI-generated summary of this filing

Updated May 19, 2026

Tandem Diabetes (TNDM) EVP Mark Novara Exercises RSUs; Shares Withheld

What Happened

Mark David Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care (TNDM), had restricted stock units (RSUs) convert to common shares on 2026-05-15. The filing shows conversion/acquisition of 10,572 shares (two entries of 76 and 10,496) at $0.00 (transaction code M), and the company withheld 7,911 shares to satisfy tax withholding (transaction code F) at $12.82 per share (withheld value ≈ $101,419). Net new shares added to his holdings from this vesting event = 2,661 shares. No open-market sale occurred; the shares were withheld by the company to cover taxes.

Key Details

Transaction date: 2026-05-15; Form 4 filed: 2026-05-19 (timely — filed within required two business days).
Converted/acquired: 10,572 shares (76 + 10,496) at $0.00 (RSU settlement; code M).
Withheld for taxes (disposed on Form 4 for withholding purposes): 7,911 shares (57 + 7,854) at $12.82 → $731 and $100,688, total ≈ $101,419 (code F). No shares sold on the open market.
Net shares retained after withholding from this vesting: 2,661 shares.
Footnotes: Shares were RSUs (F2–F6). Some awards originated May 23, 2024 and May 30, 2025; vesting schedule is 33% on 5/15 of the applicable year with remaining shares vesting in eight equal quarterly installments (see F4/F6).
Filing does not indicate a 10b5-1 plan or that shares were sold; this was a tax-withholding settlement, not a market sale.

Context

This was a routine RSU vesting and company withholding to meet tax obligations (cashless tax withholding), not an open-market sale or purchase. For retail investors, such withholdings are common and do not necessarily indicate an insider view on the company’s outlook. Transaction codes: M = exercise/conversion of derivative (here, RSU settlement); F = payment of exercise price or tax liability (here, share-withholding for taxes).

Form 4Exit

Period: 2026-05-15

EVP & CHIEF COMMERCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
2026-05-15+76→ 37,732 total
Tax Payment
Common Stock
[F1]
2026-05-15$12.82/sh−57$731→ 37,675 total
Exercise/Conversion
Common Stock
2026-05-15+10,496→ 48,171 total
Tax Payment
Common Stock
[F1]
2026-05-15$12.82/sh−7,854$100,688→ 40,317 total
Exercise/Conversion
Restricted Stock Unit
[F2][F3][F4]
2026-05-15−76→ 304 total
→ Common Stock (76 underlying)
Exercise/Conversion
Restricted Stock Unit
[F5][F3][F6]
2026-05-15−10,496→ 20,992 total
→ Common Stock (10,496 underlying)

Footnotes (6)

[F1]Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
[F2]Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
[F3]Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
[F4]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
[F5]Awarded on May 30, 2025 pursuant to the 2023 Plan.
[F6]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Signature

/s/ Shannon M. Hansen, Attorney-in-Fact for Mark D. Novara|2026-05-19

1 file